Oxybutynin is Used for treating overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence. It was first introduced by Allergan Sales Llc in its drug Oxytrol on Feb 26, 2003. Other drugs containing Oxybutynin are Gelnique 3%, Oxytrol For Women. 3 different companies have introduced drugs containing Oxybutynin.

Oxybutynin Patents

Given below is the list of patents protecting Oxybutynin, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Gelnique 3%	US7198801	Formulations for transdermal or transmucosal application	Jun 25, 2022 (Expired)	Allergan
Gelnique 3%	US7029694	Compositions and methods for transdermal oxybutynin therapy	Apr 26, 2020 (Expired)	Allergan
Gelnique 3%	US7179483	Compositions and methods for transdermal oxybutynin therapy	Apr 26, 2020 (Expired)	Allergan
Gelnique 3%	US8241662	Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy	Apr 26, 2020 (Expired)	Allergan
Oxytrol	US6743441	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	Apr 26, 2020 (Expired)	Allergan
Oxytrol	US7081249	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	Apr 26, 2020 (Expired)	Allergan
Oxytrol	US7081250	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	Apr 26, 2020 (Expired)	Allergan
Oxytrol	US7081251	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	Apr 26, 2020 (Expired)	Allergan
Oxytrol	US7081252	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	Apr 26, 2020 (Expired)	Allergan
Oxytrol	US7179483	Compositions and methods for transdermal oxybutynin therapy	Apr 26, 2020 (Expired)	Allergan
Oxytrol For Women	US6743441	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	Apr 26, 2020 (Expired)	Abbvie
Oxytrol For Women	US7081249	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	Apr 26, 2020 (Expired)	Abbvie
Oxytrol For Women	US7081250	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	Apr 26, 2020 (Expired)	Abbvie
Oxytrol For Women	US7081251	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	Apr 26, 2020 (Expired)	Abbvie
Oxytrol For Women	US7081252	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	Apr 26, 2020 (Expired)	Abbvie
Oxytrol For Women	US7179483	Compositions and methods for transdermal oxybutynin therapy	Apr 26, 2020 (Expired)	Abbvie
Oxytrol	US5601839	Triacetin as a penetration enhancer for transdermal delivery of a basic drug	Apr 26, 2015 (Expired)	Allergan
Oxytrol	US5834010	Triacetin as a penetration enhancer for transdermal delivery of a basic drug	Apr 26, 2015 (Expired)	Allergan
Oxytrol For Women	US5601839	Triacetin as a penetration enhancer for transdermal delivery of a basic drug	Apr 26, 2015 (Expired)	Abbvie
Oxytrol For Women	US5834010	Triacetin as a penetration enhancer for transdermal delivery of a basic drug	Apr 26, 2015 (Expired)	Abbvie

Add above patents to watchlist

Oxybutynin's Family Patents

Full family tree

Oxybutynin Generic API Manufacturers

Only one generic application has been filed for Oxybutynin.

Given below is the list of companies who have filed for Oxybutynin generic, along with the locations of their manufacturing plants worldwide.